CoChat

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Open access

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is increasingly appreciated as a heterogeneous disease, with factors such as microsatellite instability (MSI), cancer subsite within the colon versus rectum, and age of diagnosis associated with specific disease course and therapeutic response. Activating oncogenic mutations in KRAS and NRAS are common in CRC, driving tumor progression and influencing efficacy of both cytotoxic and targeted therapies. The RAS mutational spectrum differs substantially between tumors arising from distinct tissues. Structure-function analysis of relatively common somatic RAS mutations in G12, Q61, and other codons is characterized by differing potency and modes of action. Here we show the mutational profile of KRAS , NRAS , and the less common HRAS in 13,336 CRC tumors, comparing the frequency of specific mutations based on age of diagnosis, MSI status, and colon versus rectum subsite. We identify mutation hotspots, and unexpected differences in mutation spectrum, based on these clinical parameters.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11530-0

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overall profile of dataset. a Comparison of Foundation Medicine (FM) Inc. dataset in the present study versus a benchmark group of publicly available data (PAD) for colorectal cancer (CRC) published by Memorial Sloan-Kettering (MSK)24, the Dana Farber Cancer Institute (DFCI)23, the Genomics Evidence Neoplasia Information Exchange (GENIE)25, and The Cancer Genome Atlas (TCGA); population characteristics are also compared to overall population reported in SEER (Surveillance, Epidemiology, and End Results)1. b Flowchart and analysis tree for populations defined by FM as high level of microsatellite instability (MSI-H) or microsatellite stable (MSS), or with known tumor mutation burden (TMB); generation of MSI-H/high TMB (MT-H) and MSI-H/low TMB (MT-L) analysis cohorts. c–e Frequency of MT-H tumors based on parameters of gender (Fe, female or Ma, male) as a factor of age (<40 or ≥40 years) (c), or primary tumor site (Co, colon or Re, rectum) (d); or in combined genders, based on age and tumor site (e). Error bars, 95% confidence intervals. Statistical significance is denoted by ***p < 0.005
Fig. 1 Overall profile of dataset. a Comparison of Foundation Medicine (FM) Inc. dataset in the present study versus a benchmark group of publicly available data (PAD) for colorectal cancer (CRC) published by Memorial Sloan-Kettering (MSK)24, the Dana Farber Cancer Institute (DFCI)23, the Genomics Evidence Neoplasia Information Exchange (GENIE)25, and The Cancer Genome Atlas (TCGA); population characteristics are also compared to overall population reported in SEER (Surveillance, Epidemiology, and End Results)1. b Flowchart and analysis tree for populations defined by FM as high level of microsatellite instability (MSI-H) or microsatellite stable (MSS), or with known tumor mutation burden (TMB); generation of MSI-H/high TMB (MT-H) and MSI-H/low TMB (MT-L) analysis cohorts. c–e Frequency of MT-H tumors based on parameters of gender (Fe, female or Ma, male) as a factor of age (<40 or ≥40 years) (c), or primary tumor site (Co, colon or Re, rectum) (d); or in combined genders, based on age and tumor site (e). Error bars, 95% confidence intervals. Statistical significance is denoted by ***p < 0.005CC BY · PubMed Central
Fig. 2 Visualization of RAS mutation burden, hotspots, and functional domains. a–c Top graphs indicate mutation burden per codon of the RAS proteins KRAS (a), NRAS (b), and HRAS (c), respectively; for KRAS and NRAS, the data are plotted on a logarithmic scale. Red circle indicates missense hotspots (new and previously reported); red stem, hotspot identified in this study. Total number of mutations is provided within parenthesis. Blue triangle, previously reported hotspot not found in this study. Orange bars indicate regions where total mutation frequency is higher than expected. Critical functional domains are indicated; P-loop (salmon), switch I (cyan), switch II (green), and hypervariable region (pink). d–k Alignment of mutations to protein structure for KRAS (d–g), NRAS (h–i), and HRAS (j, k), visualized by PyMOL (http://www.pymol.org). d, f, h, j Font color indicates new hotspots (green), known colorectal cancer (CRC) hotspots (red) detected in this study, and other known hotspots not found in this study (black). d–g GDP-bound full-length KRAS structure59 (PDB code: 5TAR); two views (d, e versus f, g) of the folded protein, indicates mutations (d, f) and functional motifs (e, g). h, i NRAS structure32 (PDB code: 5UHV) indicates mutations (h) and functional motifs (i). j–k. HRAS structure32,60 (PDB code: 1CTQ), indicates mutations (j) and functional motifs (k). Color key: d, f, never mutated, gray; 1–5 times, pale yellow; 6–10 times, yellow-orange (residues 180, 164, 68, 60, 33, and 9); 11–15 times, light orange (residues 19 and 176), 16–20 times, tv_orange (residues 14 and 22); 20–100 times, orange (residues 59 and 117); > 100 times, tv_Red (residues 61, 146, and 13); and >4000 times, firebrick (residue 12). h Never mutated, gray; 1–2 times, pale yellow; 3–5 times, yellow (residues 132 and 185; 185 not shown, 5UHV lacks hypervariable region); 59 times, orange, (residue 13); 204 times, tv_Red (residue 12); 306 times, red (residue 61). j, never mutated, gray; 1 time, pale yellow; 2 times, yellow (residues 7, 20, 68, 123, 129, 131, 134, 135, 158, and 169; 169 not visualizable, 1CTQ lacks hypervariable region); 3–4 times, orange (residue 13, 59, 161, 163, and 167; back view is not visible); 6 times, tv_Red (residue 12)
Fig. 2 Visualization of RAS mutation burden, hotspots, and functional domains. a–c Top graphs indicate mutation burden per codon of the RAS proteins KRAS (a), NRAS (b), and HRAS (c), respectively; for KRAS and NRAS, the data are plotted on a logarithmic scale. Red circle indicates missense hotspots (new and previously reported); red stem, hotspot identified in this study. Total number of mutations is provided within parenthesis. Blue triangle, previously reported hotspot not found in this study. Orange bars indicate regions where total mutation frequency is higher than expected. Critical functional domains are indicated; P-loop (salmon), switch I (cyan), switch II (green), and hypervariable region (pink). d–k Alignment of mutations to protein structure for KRAS (d–g), NRAS (h–i), and HRAS (j, k), visualized by PyMOL (http://www.pymol.org). d, f, h, j Font color indicates new hotspots (green), known colorectal cancer (CRC) hotspots (red) detected in this study, and other known hotspots not found in this study (black). d–g GDP-bound full-length KRAS structure59 (PDB code: 5TAR); two views (d, e versus f, g) of the folded protein, indicates mutations (d, f) and functional motifs (e, g). h, i NRAS structure32 (PDB code: 5UHV) indicates mutations (h) and functional motifs (i). j–k. HRAS structure32,60 (PDB code: 1CTQ), indicates mutations (j) and functional motifs (k). Color key: d, f, never mutated, gray; 1–5 times, pale yellow; 6–10 times, yellow-orange (residues 180, 164, 68, 60, 33, and 9); 11–15 times, light orange (residues 19 and 176), 16–20 times, tv_orange (residues 14 and 22); 20–100 times, orange (residues 59 and 117); > 100 times, tv_Red (residues 61, 146, and 13); and >4000 times, firebrick (residue 12). h Never mutated, gray; 1–2 times, pale yellow; 3–5 times, yellow (residues 132 and 185; 185 not shown, 5UHV lacks hypervariable region); 59 times, orange, (residue 13); 204 times, tv_Red (residue 12); 306 times, red (residue 61). j, never mutated, gray; 1 time, pale yellow; 2 times, yellow (residues 7, 20, 68, 123, 129, 131, 134, 135, 158, and 169; 169 not visualizable, 1CTQ lacks hypervariable region); 3–4 times, orange (residue 13, 59, 161, 163, and 167; back view is not visible); 6 times, tv_Red (residue 12)CC BY · PubMed Central
Fig. 3 Codon missense mutational profile in KRAS-, NRAS-, and HRAS-based MSI-H/low TMB (MT-L) versus MSI-H/high TMB (MT-H) status. a Frequency of missense mutations in KRAS, NRAS, or HRAS as a factor of MT-L and MT-H status and gender in colorectal cancer (CRC) patients. ***p < 0.005. b Frequency of missense mutations affecting indicated residues in KRAS and NRAS, based on MT-H versus MT-L status. c Frequency of specific missense substitution in the G12 residue of KRAS and NRAS, based on MT-H versus MT-L status. d Frequency of missense mutations analyzed by age as a continuous variable in KRAS (in MT-L versus MT-H tumors) and NRAS (in MT-L tumors)
Fig. 3 Codon missense mutational profile in KRAS-, NRAS-, and HRAS-based MSI-H/low TMB (MT-L) versus MSI-H/high TMB (MT-H) status. a Frequency of missense mutations in KRAS, NRAS, or HRAS as a factor of MT-L and MT-H status and gender in colorectal cancer (CRC) patients. ***p < 0.005. b Frequency of missense mutations affecting indicated residues in KRAS and NRAS, based on MT-H versus MT-L status. c Frequency of specific missense substitution in the G12 residue of KRAS and NRAS, based on MT-H versus MT-L status. d Frequency of missense mutations analyzed by age as a continuous variable in KRAS (in MT-L versus MT-H tumors) and NRAS (in MT-L tumors)CC BY · PubMed Central
Fig. 4 Codon missense mutational profile in KRAS, NRAS, and HRAS analyzed by age, gender, and colon versus rectal subsite. a Frequency of mutations in the indicated codons in KRAS and NRAS dichotomized based on age (<40 or ≥40 years) in MSI-H/low TMB (MT-L) colorectal cancer (CRC) patients. *Cumulative missense mutations. b Frequency of mutations in the indicated codons in KRAS and NRAS as a factor of age as a continuous variable in MT-L CRC patients. Lower abundance missense mutations affecting A146, Q61, and K117, are analyzed as a group. c Frequency of specific missense mutations KRAS Q61 based on age (<40 or ≥40 years), gender, and tumor subsite (colon, CO, versus rectum, RE) in MT-L CRC patients. d Frequency of missense mutations considered as a factor of age as a continuous variable and gender in KRAS (in MT-L versus MSI-H/high TMB (MT-H) tumors) and NRAS (in MT-L tumors)
Fig. 4 Codon missense mutational profile in KRAS, NRAS, and HRAS analyzed by age, gender, and colon versus rectal subsite. a Frequency of mutations in the indicated codons in KRAS and NRAS dichotomized based on age (<40 or ≥40 years) in MSI-H/low TMB (MT-L) colorectal cancer (CRC) patients. *Cumulative missense mutations. b Frequency of mutations in the indicated codons in KRAS and NRAS as a factor of age as a continuous variable in MT-L CRC patients. Lower abundance missense mutations affecting A146, Q61, and K117, are analyzed as a group. c Frequency of specific missense mutations KRAS Q61 based on age (<40 or ≥40 years), gender, and tumor subsite (colon, CO, versus rectum, RE) in MT-L CRC patients. d Frequency of missense mutations considered as a factor of age as a continuous variable and gender in KRAS (in MT-L versus MSI-H/high TMB (MT-H) tumors) and NRAS (in MT-L tumors)CC BY · PubMed Central
Fig. 5 Copy number variation (CNV) and missense profile. a Frequency of amplification of the wt allele of KRAS, NRAS, or HRAS in the analyzed colorectal cancer (CRC) cohort, based on MSI-H/low TMB (MT-L) or MSI-H/high TMB (MT-H) status. b, c Frequency of amplification of the wt allele of KRAS or NRAS in MT-L CRC tumors, based on age as a continuous variable (b) or dichotomized as <40 or ≥40 (c). d. Frequency of amplification of mutated allele of KRAS is elevated in CRC tumors carrying one or more alteration (alt). *Cumulative observed missense changes. e Frequency of missense mutations in indicated codons as a factor of copy number in the mutated allele of KRAS or NRAS. f Frequency of missense mutations in indicated codons as a factor of increased copy number in the mutated allele of KRAS, in the context of indicated CNV in the wt allele of KRAS. *Cumulative observed missense changes. g Frequency of specific missense mutations in codons G12 and A146 as a factor of increased copy number in the mutated allele of KRAS, in the context of indicated CNV in the wt allele of KRAS. G12 others refers to combined rare missense mutations in G12 (e.g., G12S)
Fig. 5 Copy number variation (CNV) and missense profile. a Frequency of amplification of the wt allele of KRAS, NRAS, or HRAS in the analyzed colorectal cancer (CRC) cohort, based on MSI-H/low TMB (MT-L) or MSI-H/high TMB (MT-H) status. b, c Frequency of amplification of the wt allele of KRAS or NRAS in MT-L CRC tumors, based on age as a continuous variable (b) or dichotomized as <40 or ≥40 (c). d. Frequency of amplification of mutated allele of KRAS is elevated in CRC tumors carrying one or more alteration (alt). *Cumulative observed missense changes. e Frequency of missense mutations in indicated codons as a factor of copy number in the mutated allele of KRAS or NRAS. f Frequency of missense mutations in indicated codons as a factor of increased copy number in the mutated allele of KRAS, in the context of indicated CNV in the wt allele of KRAS. *Cumulative observed missense changes. g Frequency of specific missense mutations in codons G12 and A146 as a factor of increased copy number in the mutated allele of KRAS, in the context of indicated CNV in the wt allele of KRAS. G12 others refers to combined rare missense mutations in G12 (e.g., G12S)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 230

Metadata

Authors
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., Lieu, C., Golemis, E. A., & Meyer, J. E.
Affiliations
  • Fox Chase Cancer Center (US)
  • Foundation Medicine (United States) (US)
  • SUNY Upstate Medical University (US)
  • University of Colorado Cancer Center (US)
Corresponding author
Meyer, Joshua E.
Venue
Nature Communications
Published
2019-08-19
Volume
10
Issue
1
Pages
3722-3722
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2969694562
Cited by
215
References
58
Citations by year
2026: 12 · 2025: 25 · 2024: 44 · 2023: 25 · 2022: 35 · 2021: 42 · 2020: 30 · 2019: 2
FWCI
11.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • TUScholarShare (Temple University) (submittedVersion, cc-by)
Funders
  • Russian Government subsidy to support the Program of Competitive Growth of Kazan Federal University
  • U.S. Department of Defense (W81XWH-18-1-0148)
  • U.S. Department of Health & Human Services | NIH | Center for Information Technology (CA229259-01, DK108195)
  • Colorectal Cancer Alliance
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA006927)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
RAS mutations, colorectal cancer, KRAS, NRAS, HRAS, colon cancer, rectal cancer, age at diagnosis, microsatellite instability, mutational hotspots, somatic mutations, tumor heterogeneity
MeSH terms
Colonic Neoplasms, Female, Humans, Male, Membrane Proteins, Middle Aged, Mutation, Rectal Neoplasms, Structure-Activity Relationship, Genetic Variation, Genome, Human, Proto-Oncogene Proteins p21(ras), GTP Phosphohydrolases, Microsatellite Instability, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. https://app.cochat.ai/papers/10.1038/s41467-019-11530-0
The paper
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., Lieu, C., Golemis, E. A., & Meyer, J. E. (2019). Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications. https://doi.org/10.1038/s41467-019-11530-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.